Literature DB >> 17984411

Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system.

Elizabeth J Short1, H Lester Kirchner, George R Asaad, Sarah E Fulton, Barbara A Lewis, Nancy Klein, Sheri Eisengart, Jill Baley, Carolyn Kercsmar, Meeyoung O Min, Lynn T Singer.   

Abstract

OBJECTIVE: To investigate the relationship between the severity-based definition of bronchopulmonary dysplasia (BPD), choice of treatment, and neurocognitive outcomes at age 3 and 8 years.
DESIGN: This is a secondary analysis of data collected from a prospective, longitudinal sample of 99 children with a history of BPD.
SETTING: Children born with BPD admitted to 3 hospitals from February 1, 1989, to November 31, 1991. PARTICIPANTS: Ninety-nine children with BPD were longitudinally assessed at age 3 and 8 years. Three severity groups (mild, moderate, and severe) were formed based on gestational age and need for supplemental oxygen therapy. MAIN EXPOSURES: Supplemental oxygen therapy for 28 days or longer, birth weight less than 1500 g, and radiographic evidence of lung disease. MAIN OUTCOME MEASURES: Neurologic and medical outcomes; type of medical management; and language, achievement, and cognitive functioning were compared among the 3 severity groups.
RESULTS: Severity classification of BPD was associated with poorer outcomes. Compared with children with mild or moderate BPD, children with severe BPD performed more poorly on IQ tests (Mental Development Index, 90 vs 76.4; and Psychomotor Development Index, 92.5 vs 73.9) and language measures (total, 95 vs 82) at age 3 years and performance IQ (86 vs 75) and perceptual organization (86 vs 76) at age 8 years. Severity of BPD was not associated with choice of medical management but was related to educational interventions. Children with severe BPD received more special education services (69% vs 44%) than did children with mild BPD.
CONCLUSIONS: The severity-based classification clarifies the relationship between BPD and developmental sequelae. Children with severe BPD required more interventions at age 8 years than did children with mild or moderate BPD.

Entities:  

Mesh:

Year:  2007        PMID: 17984411     DOI: 10.1001/archpedi.161.11.1082

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  33 in total

1.  IL-18R1 and IL-18RAP SNPs may be associated with bronchopulmonary dysplasia in African-American infants.

Authors:  Joanna Floros; Douglas Londono; Derek Gordon; Patricia Silveyra; Susan L Diangelo; Rose M Viscardi; George S Worthen; Jeffrey Shenberger; Guirong Wang; Zhenwu Lin; Neal J Thomas
Journal:  Pediatr Res       Date:  2012-01       Impact factor: 3.756

Review 2.  Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Wes Onland; Anne Pmc De Jaegere; Martin Offringa; Anton van Kaam
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

3.  17-year outcome of preterm infants with diverse neonatal morbidities: Part 1--Impact on physical, neurological, and psychological health status.

Authors:  Mary C Sullivan; Michael E Msall; Robin J Miller
Journal:  J Spec Pediatr Nurs       Date:  2012-05-29       Impact factor: 1.260

4.  Behavior Profiles at 2 Years for Children Born Extremely Preterm with Bronchopulmonary Dysplasia.

Authors:  Jane E Brumbaugh; Edward F Bell; Scott F Grey; Sara B DeMauro; Betty R Vohr; Heidi M Harmon; Carla M Bann; Matthew A Rysavy; J Wells Logan; Tarah T Colaizy; Myriam A Peralta-Carcelen; Elisabeth C McGowan; Andrea F Duncan; Barbara J Stoll; Abhik Das; Susan R Hintz
Journal:  J Pediatr       Date:  2020-01-31       Impact factor: 4.406

5.  The role of plasminogen activator inhibitor-1 and angiotensin-converting enzyme gene polymorphisms in bronchopulmonary dysplasia.

Authors:  Deniz Anuk Ince; Fatma Belgin Atac; Servet Ozkiraz; Ugur Dilmen; Hande Gulcan; Aylin Tarcan; Namik Ozbek
Journal:  Genet Test Mol Biomarkers       Date:  2010-09-06

Review 6.  Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.

Authors:  Wes Onland; Martin Offringa; Anton van Kaam
Journal:  Cochrane Database Syst Rev       Date:  2017-08-24

7.  Therapeutic effects of fibroblast growth factor-10 on hyperoxia-induced bronchopulmonary dysplasia in neonatal mice.

Authors:  Tao Han; Ming Chi; Yan Wang; Yabo Mei; Qiuping Li; Mengnan Yu; Qianqian Ma; Yuhan Chen; Zhichun Feng
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 8.  Pulmonary hypertension in bronchopulmonary dysplasia.

Authors:  Sara K Berkelhamer; Karen K Mestan; Robin H Steinhorn
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

Review 9.  Developmental regulation of antioxidant enzymes and their impact on neonatal lung disease.

Authors:  Sara K Berkelhamer; Kathryn N Farrow
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

10.  Chronic lung disease and developmental delay at 2 years of age in children born before 28 weeks' gestation.

Authors:  Matthew Laughon; Michael T O'Shea; Elizabeth N Allred; Carl Bose; Karl Kuban; Linda J Van Marter; Richard A Ehrenkranz; Alan Leviton
Journal:  Pediatrics       Date:  2009-07-20       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.